In an article by Xencor President and CEO Bassil Dahiyat, published in Pharmaceutical Executive on 4 November 2009, tables are presented on new technologies for creating ‘biobetter’ follow-on biologics (FOBs) and potential ‘Big Pharma’ players in FOBs.
Innovation over imitation: New FOBs technologies, players
Biosimilars/General
|
Posted 03/02/2010
0
Post your comment
| New technologies to create the next generation of biologicals: the ‘biobetters’ | |
| Technology | Advantages |
| Antibody and protein engineering, e.g., antibody Fc engineering | - Improved potency - Superior half-life and dosing - New IP exclusivity period |
| Cell line technologies | - Improved safety - Scalability - Increased productivity |
| Manufacturing technologies | - Enhanced stability and delivery - Improved formulation |
| Potential pharmaceutical players in FOBs | |
| Company | Biologicals capabilities |
| Amgen | - Established biologicals manufacturer
- Track record of launching next-generation |
| AstraZeneca | - Medimmune facility acquisition; biologicals expertise |
| Biogen Idec | - Established biologicals manufacturer |
| Boehringer Ingelheim | - Kemwell facility collaboration - Strategic alliance with Laureate Pharma - Partnership with Inno Biologics |
| Daiichi-Sankyo | - Ranbaxy asset acquisition - License agreement with Crucell and DSM Biologics |
| Eli Lilly | - ImClone asset acquisition |
| Merck | - GlycoFi technology - Insmed facility acquisition - BioVentures Unit, plan to launch 6 FOBs 2012- 2017 |
| Boehringer Ingelheim | - Kemwell facility collaboration - Strategic alliance with Laureate Pharma - Partnership with Inno Biologics |
| Novartis | - Sandoz generics division - Dedicated biologicals unit |
| Pfizer | - Aurobindo collaboration: generics expertise - Pharmacia/Chesterfield facility acquisition - PowderMed and Rinat Neurosciences acquisitions |
(see also, Innovation over imitation - How to deliver FOBs on the bottom line, Innovation over imitation: Charting the FOBs landscape, Innovation over imitation: Tools to compete and win with ‘biobetter’ FOBs, Innovation over imitation: High-cost biosimilar FOB development, slow uptake and Innovation over imitation: ‘Biobetter’ follow-on biologics)
Reference:
Bassil Dahiyat. Innovation Over Imitation. Pharmaceutical Executive. 2009 November 4.
Source: Pharmaceutical Executive
Research
Long-term real-world safety experience of biosimilars confirms concept of biosimilarity
Budget impact analysis of Rixathon introduction in Chile for non-Hodgkin lymphoma
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
Related content
Biosimilar medicines on the Pharmaceutical Benefits Scheme in Australia
Biosimilars/General Posted 20/11/2024
SBR issues consensus on interchangeability of reference products and biosimilars
Biosimilars/General Posted 13/11/2024
Innovative direct purchase agreement sees adalimumab biosimilar prices slashed
Biosimilars/General Posted 15/10/2024
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Post your comment